Identifying as many as 50 different types of cancer in a single blood test is quite remarkable.
What if a blood test could identify signals associated with several different cancers before symptoms develop? Multi-Cancer Early Detection (MCED) testing is an emerging approach to cancer screening that uses molecular information circulating in the blood to look for possible signs of cancer. In this original interview, Ora Karp Gordon, MD, MS, FACMGG, explains how the technology works, why researchers are investigating it, and how it could eventually contribute to cancer detection and prevention.
When this article was first published in June 2024, Providence had introduced MCED testing through its Genetics and Genomics program in partnership with GRAIL, the developer of the Galleri® test.
Our earlier news article, Providence Offers Multi-Cancer Early Detection Testing, introduced the technology and its availability through Providence Southern California.
Since that introduction, additional clinical research and regulatory developments have provided a more detailed understanding of both the potential and limitations of MCED testing. The technology remains an active area of research, particularly because many cancers do not have established screening tests for people without symptoms.
An important distinction: MCED tests may detect biological signals associated with cancer, but they do not establish a cancer diagnosis, reliably detect every cancer, or replace recommended screening examinations such as mammography, colorectal cancer screening, cervical screening, and low-dose CT lung screening for eligible patients.
Dr. Ora Gordon Explains the Science Behind Multi-Cancer Early Detection
Dr. Gordon, a physician specializing in medical genetics and hereditary cancer risk, has participated in research involving cancer prevention and early detection.
During her original interview, she described the biological information that researchers can identify from a blood sample:
“We can find cells floating in the blood with small amounts of DNA that don’t belong to the person. They actually belong to the cancer, and not only can we see if there’s cancer present but we’re able to detect where it comes from: the ovary, the lung, the esophagus, or the breast tissue. This is truly transformational in how we screen for cancers.”
– Ora Gordon, MD
Dr. Gordon’s explanation introduces the concept of molecular signals associated with cancer. More specifically, the Galleri test examines fragments of cell-free DNA circulating in the blood, including DNA that may originate from cancer cells.
It does not require the collection of intact cancer cells, and the fragments being examined are still human DNA. Researchers analyze characteristic molecular patterns that may distinguish DNA released by cancer cells from DNA released by noncancerous cells.
What Is Circulating Tumor DNA?
Cells throughout the body release small fragments of genetic material into the bloodstream. These fragments are known as cell-free DNA, or cfDNA.
Some cancers also release DNA fragments into the blood. This material is often referred to as circulating tumor DNA, or ctDNA.
Because cancer cells may contain characteristic molecular changes, researchers can use advanced laboratory techniques to look for patterns that suggest a possible cancer signal.
The amount of tumor-derived DNA varies according to the cancer type, stage, biological activity, and other factors. Some cancers release very little detectable DNA, especially during their earliest stages.
For this reason, an MCED test cannot be assumed to detect every early-stage cancer.
How Galleri Uses DNA Methylation Patterns
The Galleri test analyzes DNA methylation patterns. Methylation refers to chemical modifications associated with DNA that help regulate how genes function.
Patterns of methylation can differ among healthy tissues and cancer cells. The test uses laboratory analysis and computational methods, including machine learning, to evaluate these patterns.
When a cancer-associated signal is identified, the system may predict the organ or tissue where that signal originated.
This prediction is called the cancer signal origin. It can help healthcare professionals determine which diagnostic examinations to consider next.
However, predicting a possible organ of origin is not the same as locating a confirmed tumor or establishing its stage.
Why Identifying a Possible Cancer Signal Origin Matters
Traditional cancer screening generally focuses on one organ or cancer type at a time. Mammography screens for breast cancer, for example, while low-dose CT is used for lung cancer screening in eligible high-risk individuals.
MCED technology is being investigated because some cancers, including pancreatic and certain ovarian cancers, do not currently have established population-wide screening methods for average-risk people.
If a test suggests a possible cancer signal origin, physicians may be able to direct further evaluation toward a particular organ system.
Follow-up may include imaging, laboratory studies, endoscopy, biopsy, or other procedures depending on the predicted origin and the patient’s clinical history.
A positive MCED result alone does not confirm cancer. Some positive results will not lead to an identifiable malignancy after diagnostic evaluation.
Watch Dr. Ora Gordon Discuss MCED Testing at Providence
In this original interview, Dr. Gordon explains the concept of detecting biological signals associated with several cancers from a single blood draw.
She also discusses why identifying a possible tissue of origin could help physicians direct diagnostic evaluation and how this developing technology may fit into a broader cancer prevention strategy.
Dr. Ora Gordon Provides an Overview of Multi-Cancer Early Detection
Ora Karp Gordon, MD, MS, FACMGG, discusses the science and potential applications of Multi-Cancer Early Detection testing through Providence Southern California. Original Saint John’s Cancer Institute interview from 2024.
Why Researchers Are Investigating Earlier Cancer Detection
For many cancers, the stage at diagnosis strongly influences treatment options and outcomes. Cancers discovered before they have spread may sometimes be treated with surgery, radiation, or other potentially curative approaches.
When cancer is identified at a more advanced stage, treatment may become more complex and may involve several medical specialties.
Dr. Gordon described the primary goal of early detection research:
“The goal is to detect cancer early when it can be cured.”
– Ora Gordon, MD
That goal explains much of the interest in MCED testing. However, demonstrating that a test can identify cancer signals or detect additional cancers is not the same as proving that screening with the test reduces cancer deaths.
Researchers must also determine whether a test identifies cancers early enough to improve treatment outcomes, how frequently it misses cancers, and whether additional testing causes avoidable harm.
Earlier Detection and Better Outcomes Are Not Always Equivalent
Finding cancer at an earlier stage may increase the opportunity for effective treatment, but it does not guarantee a cure.
Some cancers develop slowly and may never cause symptoms during a person’s lifetime, while others progress rapidly or may not release enough detectable DNA during their earliest stages.
Researchers evaluating screening technologies must consider factors such as overdiagnosis, false-positive results, unnecessary testing, and whether cancer-specific or overall mortality is reduced.
These questions are particularly important when a test is proposed for use among large populations of people without symptoms.
How Molecular Characteristics Influence Cancer Treatment
Dr. Gordon’s original discussion also highlighted the importance of understanding the biological characteristics of cancer.
Tumors arising in the same organ can behave differently because of variations in their molecular features, growth patterns, and other characteristics.
When cancer is confirmed, pathologists and oncologists may use biomarker testing to identify specific genetic or molecular alterations within the tumor.
For selected cancers, these findings can help determine whether targeted therapy, immunotherapy, or another treatment approach is appropriate.
However, a blood-based MCED screening result is not a substitute for the tissue analysis, pathology review, or biomarker testing required to establish a cancer diagnosis and develop an individualized treatment plan.
What Have Clinical Trials Revealed About MCED Testing?
Since Dr. Gordon’s original interview in 2024, researchers have published additional findings from clinical studies evaluating MCED technology.
These studies are helping clarify how often tests identify a cancer signal, how accurately they predict a possible tissue of origin, and what happens during the diagnostic evaluation that follows a positive result.
Importantly, research also examines whether the benefits of screening outweigh its potential harms.
The NHS-Galleri Trial
The NHS-Galleri trial was a large randomized study involving more than 140,000 participants in England. It evaluated adding the Galleri test to usual cancer screening and care.
The trial’s primary endpoint examined whether the test reduced diagnoses of stage III and stage IV cancers in a prespecified group of 12 cancer types.
Results reported in 2026 indicated that the trial did not meet its primary endpoint. Although some findings suggested differences in how cancers were detected and at which stages, those observations do not establish that the test improves survival or reduces cancer mortality.
A September 2026 publication in Nature Medicine reported additional information about the test’s performance over three annual screening rounds, including cancer detection rates, sensitivity, specificity, and accuracy in predicting cancer signal origin.
These results provide valuable evidence for the development and evaluation of MCED technologies, while also demonstrating the need for careful interpretation of screening performance.
FDA Review and the September 2026 Advisory Committee
In January 2026, GRAIL submitted its premarket approval application for the Galleri test to the U.S. Food and Drug Administration.
On September 23, 2026, an FDA advisory committee evaluated the available clinical evidence and voted favorably on the test’s safety, effectiveness, and overall benefit-risk profile, although the strength of support varied among those questions.
The advisory committee’s recommendations provide input to the FDA but do not constitute regulatory approval.
As of November 2026, the Galleri test has not been cleared or approved by the FDA. It is available in the United States as a laboratory-developed test, a different regulatory pathway from an FDA-approved screening product.
National recommendations for routine MCED screening have not been established, and evidence demonstrating a reduction in cancer deaths remains insufficient.
Why Research Continues
Several important questions remain, including:
- Which populations are most likely to benefit from MCED screening?
- How reliably can different cancers be identified during their earliest stages?
- How should physicians manage a positive result when follow-up testing does not identify cancer?
- What is the appropriate frequency of testing?
- What are the effects of false-positive results, additional procedures, anxiety, and cost?
- Can screening reduce advanced cancer diagnoses and ultimately lower cancer mortality?
These questions help determine whether MCED tests will eventually become part of widely recommended cancer screening programs.
Learn more from the National Cancer Institute’s Multi-Cancer Detection Research and Questions and Answers.
What Do MCED Test Results Mean for Patients?
MCED testing differs from diagnostic testing for someone who already has symptoms or a suspicious finding on imaging.
The test is intended to look for possible cancer-associated signals in people without an established cancer diagnosis, according to its intended use and clinical guidance.
If a Cancer Signal Is Detected
A result indicating that a cancer signal was detected means the test identified a molecular pattern that may be associated with cancer.
The result may also include a predicted cancer signal origin to help guide additional diagnostic investigation.
It does not establish that cancer is present, identify a definitive tumor location, or determine the cancer’s stage.
Physicians may recommend imaging, endoscopic examination, laboratory studies, or other tests according to the result and the patient’s medical history.
Some individuals with positive results will not have cancer confirmed during subsequent evaluation.
If No Cancer Signal Is Detected
A negative MCED result does not rule out cancer. Some cancers may be present without releasing a detectable signal, and test performance varies across cancer types and stages.
Patients should not interpret a negative result as evidence that they can postpone recommended mammograms, colorectal screening, cervical screening, or low-dose CT lung screening when eligible.
Likewise, persistent or concerning symptoms should receive appropriate diagnostic evaluation regardless of the result of an MCED test.
MCED Testing Versus Hereditary Cancer Genetic Testing
MCED screening and hereditary cancer testing answer different medical questions.
MCED testing looks for biological signals that may suggest an existing cancer in the body.
Hereditary cancer testing analyzes inherited genetic variants that may increase a person’s lifetime risk of developing certain cancers.
A person can have inherited cancer susceptibility without having cancer, and someone can develop cancer without carrying an identifiable inherited cancer-predisposing variant.
Genetic counseling may help patients understand which type of evaluation is appropriate for their personal and family history.
MCED Testing Through Providence Genetics and Genomics
Providence Southern California’s Clinical Genetics and Genomics Program currently provides information about MCED testing, hereditary cancer risk assessment, and genetic counseling.
According to Providence’s published program information, MCED testing is offered for selected adults after evaluation of individual cancer risk and other clinical considerations.
Providence identifies adults age 50 or older with additional risk factors among the populations for whom this testing may be considered. These are program and test-use considerations rather than universally established national screening recommendations.
Discussing Eligibility, Benefits, and Limitations
Before proceeding, patients should discuss what an MCED test may and may not identify, whether it is appropriate for their situation, and how abnormal results would be evaluated.
A healthcare professional can review personal and family cancer history, established screening recommendations, and other factors that may influence the decision.
Genetic counseling may also be appropriate when hereditary cancer risk is a concern.
Cost and Insurance Coverage
Providence currently lists MCED testing at approximately $700 for patients receiving genetic counseling, although pricing and services may change.
The program notes that MCED testing is not covered by most insurance plans. Coverage for genetic counseling and hereditary genetic testing may differ depending on medical indications and the patient’s health plan.
Patients should confirm current pricing, eligibility, insurance arrangements, and any applicable out-of-pocket expenses before testing.
Current Providence MCED Information and Scheduling
For the latest program information, visit Providence Multi-Cancer Early Detection Testing.
Providence’s Clinical Genetics and Genomics Program currently lists 855-306-2748 for appointments and inquiries.
Patients can also review Providence Genetics and Genomics Services for genetic counseling, hereditary cancer testing, and other services.
The Future of Multi-Cancer Early Detection Research
MCED testing represents an active area of research in oncology, molecular diagnostics, and cancer prevention.
The ability to analyze cancer-associated molecular signals from a single blood sample creates opportunities to investigate cancers that do not currently have established screening methods.
At the same time, clinical research must determine whether using such tests improves meaningful outcomes for patients, including reducing advanced cancer diagnoses, unnecessary procedures, and cancer-related deaths.
Dr. Gordon’s original 2024 interview offers an introduction to the technology and the reasons clinicians and researchers are interested in its potential.
Subsequent clinical studies and regulatory evaluation provide necessary context for patients considering the test today. Together, they illustrate both the possibilities of molecular screening and the importance of evaluating new technologies through rigorous clinical evidence.
Supporting Informed Decisions About Cancer Screening and Genetic Risk
Multi-Cancer Early Detection technology offers a new way to investigate biological signals associated with several cancers from a single blood sample. As Dr. Ora Gordon explains, the potential to identify a cancer signal and predict its possible origin has important implications for the future of cancer detection. Continued research, however, is essential to establish which patients benefit, how results should be interpreted, and whether screening leads to better long-term outcomes.
Patients interested in MCED testing or hereditary cancer evaluation can learn more through Providence’s Multi-Cancer Early Detection Program, explore Ora Karp Gordon, MD, MS, FACMGG, and review cancer research initiatives at Saint John’s Cancer Institute. MCED testing should complement—not replace—established screening recommendations and appropriate evaluation of symptoms.
Sources & Further Reading
- Providence — Multi-Cancer Early Detection Blood Test: Program Information, Eligibility, and Safety
- Providence — Clinical Genetics and Genomics Program
- National Cancer Institute — Questions and Answers About Multi-Cancer Detection Tests
- National Cancer Institute — Cancer Screening Overview and Multi-Cancer Detection
- Nature Medicine (2026) — Performance of a Multi-Cancer Early Detection Test in the Randomized NHS-Galleri Trial
- U.S. Food and Drug Administration — September 23, 2026 Advisory Committee Meeting Summary
- Saint John’s Cancer Institute — Ora Karp Gordon, MD, MS, FACMGG
- Saint John’s Cancer Institute — Providence Offers Multi-Cancer Early Detection Testing
